SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 9, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	8,136,747	8,700,602	7,862,650	5,646,385	7,612,048	13,234,939
Market Cap Growth	-0.10%	10.66%	39.25%	-25.82%	-42.48%	-
Enterprise Value	8,007,966	8,637,734	7,807,605	5,442,304	7,267,516	12,840,764
Last Close Price	103900.00	111100.00	100400.00	72100.00	97200.00	169000.00
PE Ratio	31.79	36.14	-	-	117.39	-
Forward PE	41.37	73.81	-	-	-	-
PS Ratio	13.12	15.89	22.16	22.94	18.18	509.06
PB Ratio	13.25	15.16	24.50	17.84	17.14	34.92
P/TBV Ratio	13.86	16.24	29.59	18.86	17.90	36.83
P/FCF Ratio	80.56	93.05	-	-	-	-
P/OCF Ratio	78.82	91.68	-	-	-	-
EV/Sales Ratio	12.91	15.77	22.00	22.11	17.36	493.89
EV/EBITDA Ratio	63.03	75.93	-	-	68.18	-
EV/EBIT Ratio	73.24	89.66	-	-	76.53	-
EV/FCF Ratio	79.29	92.38	-	-	-	-
Debt / Equity Ratio	0.12	0.32	0.56	0.49	0.04	0.05
Debt / EBITDA Ratio	0.45	1.62	-	-	0.15	-
Debt / FCF Ratio	0.74	1.97	-	-	-	-
Asset Turnover	0.70	0.62	0.51	0.38	0.73	0.08
Inventory Turnover	0.36	0.40	0.35	0.53	0.60	0.13
Quick Ratio	1.54	1.26	1.47	2.28	2.64	5.67
Current Ratio	2.19	1.64	2.02	2.99	3.18	6.16
Return on Equity (ROE)	49.08%	50.72%	-11.10%	-36.66%	15.75%	-135.18%
Return on Assets (ROA)	10.38%	6.84%	-3.38%	-12.53%	10.38%	-46.83%
Return on Capital (ROIC)	14.56%	9.58%	-4.83%	-17.57%	13.84%	-60.65%
Return on Capital Employed (ROCE)	21.40%	15.00%	-	-	19.20%	-
Earnings Yield	3.15%	2.77%	-0.42%	-2.47%	0.85%	-1.87%
FCF Yield	1.24%	1.07%	-1.23%	-2.92%	-1.28%	-1.68%
Buyback Yield / Dilution	-	-	-	-	-9.12%	-10.41%

Updated Mar 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.